| Identification | Back Directory | [Name]
L 748,337 | [CAS]
244192-94-7 | [Synonyms]
L-748
L 748,337
L748337,L-748337
N-[[3-[(2S)-3-[2-[4-(benzenesulfonamido)phenyl]ethylamino]-2-hydroxypropoxy]phenyl]methyl]acetamide
N-[[3-[(2S)-2-HYDROXY-3-[[2-[4-[(PHENYLSULFONYL)AMINO]PHENYL]ETHYL]AMINO]PROPOXY]PHENYL]METHYL]-ACETAMIDE
Acetamide, N-[[3-[(2S)-2-hydroxy-3-[[2-[4-[(phenylsulfonyl)amino]phenyl]ethyl]amino]propoxy]phenyl]methyl]- | [Molecular Formula]
C26H31N3O5S | [MDL Number]
MFCD10687097 | [MOL File]
244192-94-7.mol | [Molecular Weight]
497.61 |
| Hazard Information | Back Directory | [Uses]
L-748,337 is a selective competitive β3-adrenoceptor antagonist. | [Biological Activity]
Competitive β 3 -adrenoceptor antagonist that displays selectivity over β 1 and β 2 receptors (K i values are 4.0, 204 and 390 nM for β 3 -, β 2 - and β 1 -adrenoceptors respectively). Inhibits cAMP accumulation in response to isoproterenol (IC 50 = 6 nM). | [in vivo]
L-748337 (intraperitoneal injection; 5 mg/kg; beginning 10 days until D18) decreases the growth of melanoma induced by B16F10 cell inoculation and decreases tumor vasculature in mice[1]. | Animal Model: | Fifty male C57BL/6 J mice (8 weeks of age) bearing syngeneic B16F10 cell[1] | | Dosage: | 5 mg/kg | | Administration: | Beginning 10 days until D18 | | Result: | Exhibited anti-cancer effects. |
| [IC 50]
Beta-3 adrenergic receptor: 4 nM (Ki); Beta-2 adrenergic receptor: 204 nM (Ki); Beta-1 adrenergic receptor: 390 nM (Ki) | [storage]
Store at -20°C |
|
| Company Name: |
|
| Tel: |
821-50328103-801 18930552037 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList13285/0.htm |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
R&D Systems, Inc
|
| Tel: |
18003437475 18003437475 |
| Website: |
www.rndsystems.com |
|